Rabeprazole-based eradication therapy for Helicobacter pylori: A large-scale study in Japan

H. Kuwayama; K. Asaka; T. Sugiyama; Y. Fukuda; N. Aoyama; Y. Hirai; T. Fujioka; Gakuyo Karasawa; Ryo Uyama; Mototsugu Kato; Yuichi Shimizu; Souichi Nakagawa; Ken Nishi; Shigeru Ozasa; Mineo Kudo; Takahiro Kamata; Masao Saito; Naoyuki Kawamura; Masako Tsuyuguchi; Hiroko Ooizumi; Takeaki Kobayashi; Asako Iijima; Tsuyoshi Yabana; Kazuyoshi Yamashita; Youji Harada; Teitetsu Niido; Yuri Yasuda; Yoko Iga; Hajime Kuwayama; Morio Takahashi; Hironobu Takada; Hiroshi Takada; Shigeki Oka; Hiroki Ichimura; Eiko Makino; Kazumasa Miki; Jun Miwa; Yasuo Matsubara; Takashige Tomita; Shigeru Koyama; Nobuhiro Sakaki; Masahiko Takahashi; Haruko Yokoyama; Yuji Koike; Tuyo To; Yoshiharu Satake; Makiyo Machida; Takashi Kawai; Satoru Taira; Kenji Nukaga; Naomi Uemura; Jyunichi Akiyama; Yuko Hiraga; Hitohiko Koizuka; Shigeaki Yasaka; Ryosuke Tajiri; Masao Kobayakawa; Akitaka Takahara; Mika Shimamoto; Hiroshi Murata; Toshihide Okada; Yoshihide Fujiyama; Shigeki Koyama; Masaya Sasaki; Tomoyuki Tsujikawa; Izumi Ishizuka; Kiyoshi Ashida; Hajime Takahashi; Takumi Fukuchi; Naomi Kiyota; Hiroshi Yamashita; Reiko Tsukamoto; Hiroshi Ito; Tomohiro Nishide; Haruki Kato; Takashi Ando; Koichi Terao; Nobuo Aoyama; Daisuke Shirasaka; Takao Tamura; Shunichi Yoshida; Seiichi Hirano; Yoshihiro Fukuda; Kazutoshi Hori; Toshihiko Tomita; Tahashi Sakagami; Kazuhiko Inoue; Mutsumi Hananoki; Norio Miyashima; Hirotsugu Okuda; Kazuhiro Harada; Toshihiro Honda; Masaharu Takeda; Ken Haruma; Toru Hidaka; Hiroaki Oogoshi; Shinji Nagata; Akira Tari; Hiroshi Tani; Hiroshi Mieno; Mitsuhiro Mihara; Yoshihiro Wada; Tomohiko Shimatani; Masaki Inoue; Takashi Kobayashi; Kazuhiko Yamauchi; Makoto Tsugita; Nobutoshi Kuniyoshi; Kazuma Fujimoto; Ryuichi Iwakiri; Hiroyuki Sakata; Seiji Tsunada; Akifumi Ootani; Atsushi Kikkawa; Yoshihiro Eriguchi; Koji Fukuyama; Masahiro Hattori; Tomofumi Tanaka; Kiwamu Hasuda; Hideyo Goto; Toshio Fujioka; Ryugo Sato; Kazunari Murakami; Masaaki Kodama; Tadayoshi Okimoto; Hajime Miyajima; Masami Ono; Tsuyoshi Arita; Syunzo Sato; Hisanori Abe

doi:10.1111/j.1365-2036.2007.03298.x

Rabeprazole-based eradication therapy for Helicobacter pylori: A large-scale study in Japan

H. Kuwayama, K. Asaka, T. Sugiyama, Y. Fukuda, N. Aoyama, Y. Hirai, T. Fujioka, Gakuyo Karasawa, Ryo Uyama, Mototsugu Kato, Yuichi Shimizu, Souichi Nakagawa, Ken Nishi, Shigeru Ozasa, Mineo Kudo, Takahiro Kamata, Masao Saito, Naoyuki Kawamura, Masako Tsuyuguchi, Hiroko OoizumiTakeaki Kobayashi, Asako Iijima, Tsuyoshi Yabana, Kazuyoshi Yamashita, Youji Harada, Teitetsu Niido, Yuri Yasuda, Yoko Iga, Hajime Kuwayama, Morio Takahashi, Hironobu Takada, Hiroshi Takada, Shigeki Oka, Hiroki Ichimura, Eiko Makino, Kazumasa Miki, Jun Miwa, Yasuo Matsubara, Takashige Tomita, Shigeru Koyama, Nobuhiro Sakaki, Masahiko Takahashi, Haruko Yokoyama, Yuji Koike, Tuyo To, Yoshiharu Satake, Makiyo Machida, Takashi Kawai, Satoru Taira, Kenji Nukaga, Naomi Uemura, Jyunichi Akiyama, Yuko Hiraga, Hitohiko Koizuka, Shigeaki Yasaka, Ryosuke Tajiri, Masao Kobayakawa, Akitaka Takahara, Mika Shimamoto, Hiroshi Murata, Toshihide Okada, Yoshihide Fujiyama, Shigeki Koyama, Masaya Sasaki, Tomoyuki Tsujikawa, Izumi Ishizuka, Kiyoshi Ashida, Hajime Takahashi, Takumi Fukuchi, Naomi Kiyota, Hiroshi Yamashita, Reiko Tsukamoto, Hiroshi Ito, Tomohiro Nishide, Haruki Kato, Takashi Ando, Koichi Terao, Nobuo Aoyama, Daisuke Shirasaka, Takao Tamura, Shunichi Yoshida, Seiichi Hirano, Yoshihiro Fukuda, Kazutoshi Hori, Toshihiko Tomita, Tahashi Sakagami, Kazuhiko Inoue, Mutsumi Hananoki, Norio Miyashima, Hirotsugu Okuda, Kazuhiro Harada, Toshihiro Honda, Masaharu Takeda, Ken Haruma, Toru Hidaka, Hiroaki Oogoshi, Shinji Nagata, Akira Tari, Hiroshi Tani, Hiroshi Mieno, Mitsuhiro Mihara, Yoshihiro Wada, Tomohiko Shimatani, Masaki Inoue, Takashi Kobayashi, Kazuhiko Yamauchi, Makoto Tsugita, Nobutoshi Kuniyoshi, Kazuma Fujimoto, Ryuichi Iwakiri, Hiroyuki Sakata, Seiji Tsunada, Akifumi Ootani, Atsushi Kikkawa, Yoshihiro Eriguchi, Koji Fukuyama, Masahiro Hattori, Tomofumi Tanaka, Kiwamu Hasuda, Hideyo Goto, Toshio Fujioka, Ryugo Sato, Kazunari Murakami, Masaaki Kodama, Tadayoshi Okimoto, Hajime Miyajima, Masami Ono, Tsuyoshi Arita, Syunzo Sato, Hisanori Abe

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

55 被引用数 (Scopus)

抄録

Background: Large-scale studies of rabeprazole-based Helicobacter pylori eradication therapy have not been reported in Japan. Aims: To evaluate H. pylori eradication by rabeprazole-based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages. Methods: From 35 centres 479 H. pylori-positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days); Group 2 (10 mg, 750 mg, 400 mg); Group 3 (20 mg, 750 mg, 200 mg) and Group 4 (20 mg, 750 mg, 400 mg). Results: Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1-4, respectively. The eradication rate was 95% (360 of 379) for clarithromycin- susceptible strains, and 50% (30 of 60) for clarithromycin-resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively. Conclusions: Rabeprazole-based therapies achieved 50% eradication of clarithromycin-resistant H. pylori, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first-line proton pump inhibitor-based triple therapy for H. pylori.

本文言語	英語
ページ（範囲）	1105-1113
ページ数	9
ジャーナル	Alimentary Pharmacology and Therapeutics
巻	25
号	9
DOI	https://doi.org/10.1111/j.1365-2036.2007.03298.x
出版ステータス	出版済み - 5月 2007
外部発表	はい

!!!All Science Journal Classification (ASJC) codes

肝臓学
消化器病学
薬理学（医学）

文献へのアクセス

10.1111/j.1365-2036.2007.03298.x

他のファイルとリンク

引用スタイル

Kuwayama, H., Asaka, K., Sugiyama, T., Fukuda, Y., Aoyama, N., Hirai, Y., Fujioka, T., Karasawa, G., Uyama, R., Kato, M., Shimizu, Y., Nakagawa, S., Nishi, K., Ozasa, S., Kudo, M., Kamata, T., Saito, M., Kawamura, N., Tsuyuguchi, M., ... Abe, H. (2007). Rabeprazole-based eradication therapy for Helicobacter pylori: A large-scale study in Japan. Alimentary Pharmacology and Therapeutics, 25(9), 1105-1113. https://doi.org/10.1111/j.1365-2036.2007.03298.x

Kuwayama, H, Asaka, K, Sugiyama, T, Fukuda, Y, Aoyama, N, Hirai, Y, Fujioka, T, Karasawa, G, Uyama, R, Kato, M, Shimizu, Y, Nakagawa, S, Nishi, K, Ozasa, S, Kudo, M, Kamata, T, Saito, M, Kawamura, N, Tsuyuguchi, M, Ooizumi, H, Kobayashi, T, Iijima, A, Yabana, T, Yamashita, K, Harada, Y, Niido, T, Yasuda, Y, Iga, Y, Kuwayama, H, Takahashi, M, Takada, H, Takada, H, Oka, S, Ichimura, H, Makino, E, Miki, K, Miwa, J, Matsubara, Y, Tomita, T, Koyama, S, Sakaki, N, Takahashi, M, Yokoyama, H, Koike, Y, To, T, Satake, Y, Machida, M, Kawai, T, Taira, S, Nukaga, K, Uemura, N, Akiyama, J, Hiraga, Y, Koizuka, H, Yasaka, S, Tajiri, R, Kobayakawa, M, Takahara, A, Shimamoto, M, Murata, H, Okada, T, Fujiyama, Y, Koyama, S, Sasaki, M, Tsujikawa, T, Ishizuka, I, Ashida, K, Takahashi, H, Fukuchi, T, Kiyota, N, Yamashita, H, Tsukamoto, R, Ito, H, Nishide, T, Kato, H, Ando, T, Terao, K, Aoyama, N, Shirasaka, D, Tamura, T, Yoshida, S, Hirano, S, Fukuda, Y, Hori, K, Tomita, T, Sakagami, T, Inoue, K, Hananoki, M, Miyashima, N, Okuda, H, Harada, K, Honda, T, Takeda, M, Haruma, K, Hidaka, T, Oogoshi, H, Nagata, S, Tari, A, Tani, H, Mieno, H, Mihara, M, Wada, Y, Shimatani, T, Inoue, M, Kobayashi, T, Yamauchi, K, Tsugita, M, Kuniyoshi, N, Fujimoto, K, Iwakiri, R, Sakata, H, Tsunada, S, Ootani, A, Kikkawa, A, Eriguchi, Y, Fukuyama, K, Hattori, M, Tanaka, T, Hasuda, K, Goto, H, Fujioka, T, Sato, R, Murakami, K, Kodama, M, Okimoto, T, Miyajima, H, Ono, M, Arita, T, Sato, S & Abe, H 2007, 'Rabeprazole-based eradication therapy for Helicobacter pylori: A large-scale study in Japan', Alimentary Pharmacology and Therapeutics, vol. 25, no. 9, pp. 1105-1113. https://doi.org/10.1111/j.1365-2036.2007.03298.x

@article{2732e34effbe40c78ffab0b6a4c79b1f,

title = "Rabeprazole-based eradication therapy for Helicobacter pylori: A large-scale study in Japan",

abstract = "Background: Large-scale studies of rabeprazole-based Helicobacter pylori eradication therapy have not been reported in Japan. Aims: To evaluate H. pylori eradication by rabeprazole-based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages. Methods: From 35 centres 479 H. pylori-positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days); Group 2 (10 mg, 750 mg, 400 mg); Group 3 (20 mg, 750 mg, 200 mg) and Group 4 (20 mg, 750 mg, 400 mg). Results: Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1-4, respectively. The eradication rate was 95% (360 of 379) for clarithromycin- susceptible strains, and 50% (30 of 60) for clarithromycin-resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively. Conclusions: Rabeprazole-based therapies achieved 50% eradication of clarithromycin-resistant H. pylori, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first-line proton pump inhibitor-based triple therapy for H. pylori.",

author = "H. Kuwayama and K. Asaka and T. Sugiyama and Y. Fukuda and N. Aoyama and Y. Hirai and T. Fujioka and Gakuyo Karasawa and Ryo Uyama and Mototsugu Kato and Yuichi Shimizu and Souichi Nakagawa and Ken Nishi and Shigeru Ozasa and Mineo Kudo and Takahiro Kamata and Masao Saito and Naoyuki Kawamura and Masako Tsuyuguchi and Hiroko Ooizumi and Takeaki Kobayashi and Asako Iijima and Tsuyoshi Yabana and Kazuyoshi Yamashita and Youji Harada and Teitetsu Niido and Yuri Yasuda and Yoko Iga and Hajime Kuwayama and Morio Takahashi and Hironobu Takada and Hiroshi Takada and Shigeki Oka and Hiroki Ichimura and Eiko Makino and Kazumasa Miki and Jun Miwa and Yasuo Matsubara and Takashige Tomita and Shigeru Koyama and Nobuhiro Sakaki and Masahiko Takahashi and Haruko Yokoyama and Yuji Koike and Tuyo To and Yoshiharu Satake and Makiyo Machida and Takashi Kawai and Satoru Taira and Kenji Nukaga and Naomi Uemura and Jyunichi Akiyama and Yuko Hiraga and Hitohiko Koizuka and Shigeaki Yasaka and Ryosuke Tajiri and Masao Kobayakawa and Akitaka Takahara and Mika Shimamoto and Hiroshi Murata and Toshihide Okada and Yoshihide Fujiyama and Shigeki Koyama and Masaya Sasaki and Tomoyuki Tsujikawa and Izumi Ishizuka and Kiyoshi Ashida and Hajime Takahashi and Takumi Fukuchi and Naomi Kiyota and Hiroshi Yamashita and Reiko Tsukamoto and Hiroshi Ito and Tomohiro Nishide and Haruki Kato and Takashi Ando and Koichi Terao and Nobuo Aoyama and Daisuke Shirasaka and Takao Tamura and Shunichi Yoshida and Seiichi Hirano and Yoshihiro Fukuda and Kazutoshi Hori and Toshihiko Tomita and Tahashi Sakagami and Kazuhiko Inoue and Mutsumi Hananoki and Norio Miyashima and Hirotsugu Okuda and Kazuhiro Harada and Toshihiro Honda and Masaharu Takeda and Ken Haruma and Toru Hidaka and Hiroaki Oogoshi and Shinji Nagata and Akira Tari and Hiroshi Tani and Hiroshi Mieno and Mitsuhiro Mihara and Yoshihiro Wada and Tomohiko Shimatani and Masaki Inoue and Takashi Kobayashi and Kazuhiko Yamauchi and Makoto Tsugita and Nobutoshi Kuniyoshi and Kazuma Fujimoto and Ryuichi Iwakiri and Hiroyuki Sakata and Seiji Tsunada and Akifumi Ootani and Atsushi Kikkawa and Yoshihiro Eriguchi and Koji Fukuyama and Masahiro Hattori and Tomofumi Tanaka and Kiwamu Hasuda and Hideyo Goto and Toshio Fujioka and Ryugo Sato and Kazunari Murakami and Masaaki Kodama and Tadayoshi Okimoto and Hajime Miyajima and Masami Ono and Tsuyoshi Arita and Syunzo Sato and Hisanori Abe",

year = "2007",

month = may,

doi = "10.1111/j.1365-2036.2007.03298.x",

language = "English",

volume = "25",

pages = "1105--1113",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Rabeprazole-based eradication therapy for Helicobacter pylori

T2 - A large-scale study in Japan

AU - Kuwayama, H.

AU - Asaka, K.

AU - Sugiyama, T.

AU - Fukuda, Y.

AU - Aoyama, N.

AU - Hirai, Y.

AU - Fujioka, T.

AU - Karasawa, Gakuyo

AU - Uyama, Ryo

AU - Kato, Mototsugu

AU - Shimizu, Yuichi

AU - Nakagawa, Souichi

AU - Nishi, Ken

AU - Ozasa, Shigeru

AU - Kudo, Mineo

AU - Kamata, Takahiro

AU - Saito, Masao

AU - Kawamura, Naoyuki

AU - Tsuyuguchi, Masako

AU - Ooizumi, Hiroko

AU - Kobayashi, Takeaki

AU - Iijima, Asako

AU - Yabana, Tsuyoshi

AU - Yamashita, Kazuyoshi

AU - Harada, Youji

AU - Niido, Teitetsu

AU - Yasuda, Yuri

AU - Iga, Yoko

AU - Kuwayama, Hajime

AU - Takahashi, Morio

AU - Takada, Hironobu

AU - Takada, Hiroshi

AU - Oka, Shigeki

AU - Ichimura, Hiroki

AU - Makino, Eiko

AU - Miki, Kazumasa

AU - Miwa, Jun

AU - Matsubara, Yasuo

AU - Tomita, Takashige

AU - Koyama, Shigeru

AU - Sakaki, Nobuhiro

AU - Takahashi, Masahiko

AU - Yokoyama, Haruko

AU - Koike, Yuji

AU - To, Tuyo

AU - Satake, Yoshiharu

AU - Machida, Makiyo

AU - Kawai, Takashi

AU - Taira, Satoru

AU - Nukaga, Kenji

AU - Uemura, Naomi

AU - Akiyama, Jyunichi

AU - Hiraga, Yuko

AU - Koizuka, Hitohiko

AU - Yasaka, Shigeaki

AU - Tajiri, Ryosuke

AU - Kobayakawa, Masao

AU - Takahara, Akitaka

AU - Shimamoto, Mika

AU - Murata, Hiroshi

AU - Okada, Toshihide

AU - Fujiyama, Yoshihide

AU - Koyama, Shigeki

AU - Sasaki, Masaya

AU - Tsujikawa, Tomoyuki

AU - Ishizuka, Izumi

AU - Ashida, Kiyoshi

AU - Takahashi, Hajime

AU - Fukuchi, Takumi

AU - Kiyota, Naomi

AU - Yamashita, Hiroshi

AU - Tsukamoto, Reiko

AU - Ito, Hiroshi

AU - Nishide, Tomohiro

AU - Kato, Haruki

AU - Ando, Takashi

AU - Terao, Koichi

AU - Aoyama, Nobuo

AU - Shirasaka, Daisuke

AU - Tamura, Takao

AU - Yoshida, Shunichi

AU - Hirano, Seiichi

AU - Fukuda, Yoshihiro

AU - Hori, Kazutoshi

AU - Tomita, Toshihiko

AU - Sakagami, Tahashi

AU - Inoue, Kazuhiko

AU - Hananoki, Mutsumi

AU - Miyashima, Norio

AU - Okuda, Hirotsugu

AU - Harada, Kazuhiro

AU - Honda, Toshihiro

AU - Takeda, Masaharu

AU - Haruma, Ken

AU - Hidaka, Toru

AU - Oogoshi, Hiroaki

AU - Nagata, Shinji

AU - Tari, Akira

AU - Tani, Hiroshi

AU - Mieno, Hiroshi

AU - Mihara, Mitsuhiro

AU - Wada, Yoshihiro

AU - Shimatani, Tomohiko

AU - Inoue, Masaki

AU - Kobayashi, Takashi

AU - Yamauchi, Kazuhiko

AU - Tsugita, Makoto

AU - Kuniyoshi, Nobutoshi

AU - Fujimoto, Kazuma

AU - Iwakiri, Ryuichi

AU - Sakata, Hiroyuki

AU - Tsunada, Seiji

AU - Ootani, Akifumi

AU - Kikkawa, Atsushi

AU - Eriguchi, Yoshihiro

AU - Fukuyama, Koji

AU - Hattori, Masahiro

AU - Tanaka, Tomofumi

AU - Hasuda, Kiwamu

AU - Goto, Hideyo

AU - Fujioka, Toshio

AU - Sato, Ryugo

AU - Murakami, Kazunari

AU - Kodama, Masaaki

AU - Okimoto, Tadayoshi

AU - Miyajima, Hajime

AU - Ono, Masami

AU - Arita, Tsuyoshi

AU - Sato, Syunzo

AU - Abe, Hisanori

PY - 2007/5

Y1 - 2007/5

N2 - Background: Large-scale studies of rabeprazole-based Helicobacter pylori eradication therapy have not been reported in Japan. Aims: To evaluate H. pylori eradication by rabeprazole-based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages. Methods: From 35 centres 479 H. pylori-positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days); Group 2 (10 mg, 750 mg, 400 mg); Group 3 (20 mg, 750 mg, 200 mg) and Group 4 (20 mg, 750 mg, 400 mg). Results: Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1-4, respectively. The eradication rate was 95% (360 of 379) for clarithromycin- susceptible strains, and 50% (30 of 60) for clarithromycin-resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively. Conclusions: Rabeprazole-based therapies achieved 50% eradication of clarithromycin-resistant H. pylori, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first-line proton pump inhibitor-based triple therapy for H. pylori.

AB - Background: Large-scale studies of rabeprazole-based Helicobacter pylori eradication therapy have not been reported in Japan. Aims: To evaluate H. pylori eradication by rabeprazole-based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages. Methods: From 35 centres 479 H. pylori-positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days); Group 2 (10 mg, 750 mg, 400 mg); Group 3 (20 mg, 750 mg, 200 mg) and Group 4 (20 mg, 750 mg, 400 mg). Results: Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1-4, respectively. The eradication rate was 95% (360 of 379) for clarithromycin- susceptible strains, and 50% (30 of 60) for clarithromycin-resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively. Conclusions: Rabeprazole-based therapies achieved 50% eradication of clarithromycin-resistant H. pylori, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first-line proton pump inhibitor-based triple therapy for H. pylori.

UR - http://www.scopus.com/inward/record.url?scp=34247175345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247175345&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2007.03298.x

DO - 10.1111/j.1365-2036.2007.03298.x

M3 - Article

C2 - 17439512

AN - SCOPUS:34247175345

SN - 0269-2813

VL - 25

SP - 1105

EP - 1113

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 9

ER -

Rabeprazole-based eradication therapy for Helicobacter pylori: A large-scale study in Japan

抄録

!!!All Science Journal Classification (ASJC) codes

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル